中草药叶下珠不同品种和制剂体外抗乙型肝炎病毒的实验研究

以２．２．１５细胞为模型，对不同品种、剂型和添加成份的叶下珠提取物进行了体外抗乙型肝炎病毒（ＨＢＶ）活性的研究。结果显示，七种受试药物体外均有不同程度的抗ＨＢＶ活性。其中以沱茶珍珠草、胶囊１号作用最明显，在浓度为５００ｍｇ／Ｌ时对ＨＢｓＡｇ的抑制率可达１００％，而未显示出明显的细胞毒性。Ｓｏｕｔｈｅｒｎ印迹杂交显示，胶囊１号对细胞内外ＨＢＶＤＮＡ的抑制呈剂量依赖型。还观察到，药物对病毒颗粒产生的抑制不仅在转录前水平，可能对ｍＲＮＡ的翻译水平也有影响。     

中草药抗乙型肝炎病毒活性及其作用机理体外实验研究

用２．２．１５细胞株体外抗乙型肝炎病毒（ＨＢＶ）药物实验模型，对４种中草药制剂体外抗ＨＢＶ活性及其机理进行了评价，结果表明；４种中草药对细胞的５０％毒性浓度（ＣＤ５０）分别为乾坤宁〉６４０ｍｇ／Ｌ，双黄连针剂〉６４０ｍｇ／Ｌ，复方仙茅浸膏水提取液１６０ｇ／Ｌ（生药计算），复方黄芪浸膏水提取液３２０ｇ／Ｌ（生药计算）。对病毒复制指标ＨＢｓＡｇ，ＨＢｅＡｇ和细胞内ＨＢＶＤＮＡ的５０％抑制浓度（ＩＤ５０     

促肝细胞生长素抗乙型肝炎病毒的体外效应观察

促肝细胞生长素抗乙型肝炎病毒的体外效应观察彭齐荣，余宙耀，李灼亮，涂荫国促肝细胞生长素（ＰＨＧＦ）已广泛地用于临床，但有无抗病毒作用目前尚无结论，我们以转染乙型肝炎病毒（ＨＢＶ）的ＨｅｐＧ２细胞（２２１５细胞）为模型，探讨其体外抗－ＨＢＶ的活性。ＰＨ...     

抗肾综合征出血热病毒人单克隆抗体杂交瘤细胞株的建立及初步鉴定

以亲和层析技术纯化的肾综合征出血热病毒（ＨＦＲＳＶ）结构蛋白（５５０００，６７０００）为特异性抗原，体外免疫正常人外周血淋巴细胞（ＰＢＬ），然后将体外免疫的淋巴细胞与人－鼠种间杂交瘤细胞（Ｋ６Ｈ６／Ｂ５）融合，经ＥＬＩＳＡ间接法筛选出２株（２Ｄ５，１Ｂ７）分泌抗－ＨＦＲＳＶ人单克隆抗体（Ｈ－ＭｃＡｂ）杂交瘤细胞株，４次克隆化后，１００％阳性。对２Ｄ５株初步鉴定表明，其抗体类型为ＩｇＧ１；培养上清中抗体浓度为２０～３０μｇ／ｍｌ；特异性免疫荧光反应证明２Ｄ５株Ｈ－ＭｃＡｂ是ＨＦＲＳＶ特异性；中和效价为１∶１６０；体外连续传代６个月仍稳定分泌抗体。     

针对包装信号起始区的硫代反义核苷酸抗HBV的研究

目的筛选高效特异的抗ＨＢＶ反义核酸药物。方法针对ＨＢＶ包装信号ε起始区设计并合成硫代反义寡聚核苷酸（ｓ－ａｓＯＤＮ）片段，通过ＥＬＩＳＡ检测法、ＭＴＴ法、电子显微镜等观察，研究此ｓ－ａｓＯＤＮ对ＨＢｓＡｇ、ＨＢｅＡｇ和ＨＢｃＡｇ表达，以及对细胞毒性，细胞形态的影响。结果针对ε起始区的ｓ－ａｓＯＤＮ显著抑制ＨＢｓＡｇ、ＨＢｅＡｇ和ＨＢｃＡｇ的表达，其中，对ＨＢｅＡｇ和ＨＢｃＡｇ的抑制率分别为３８．１％和５８．７％高于Ｓ基因起始区（３２．１％和３７．２％，Ｐ＜０．０１），对ＨＢｓＡｇ抑制率为８２％，低于Ｓ基因起始区（９３．４１％），在实验浓度下ｓ－ａｓＯＤＮ对细胞无毒性，对细胞形态无影响。结论ＨＢＶ包装信号区是反义核酸抗ＨＢＶ复制研究的重要的靶序列选择区域。     

应用S基因转染的Sp2／0细胞作为靶细胞研究HBV基因疫？…

构建编码ＨＢｓＡｇ蛋白的重组真核表达质粒ｐＣＲ３．１－Ｓ作为ＨＢＶ基因疫苗,免疫接种Ｂａｌｂ／ｃ小鼠,以重组质粒ｐＣＲ３．１－Ｓ转染的Ｓｐ２／０细胞作为靶细胞,采用＾５１Ｃｒ ４ｈ释放法,体外检测免疫小鼠的淋巴细胞杀伤功能。结果显示,与空载体对照组相比较,ＨＢＶ基因疫苗可诱导Ｂａｌｂ／ｃ小鼠产生ＨＢＶ特生细胞毒性Ｔ细胞应答,提示以Ｓｐ２／０基因转染的细胞作为靶细胞,检测免疫Ｂａｌｂ／ｃ小鼠淋巴细胞     

合成多肽体外诱导乙肝病毒抗原特异性CTL杀伤机制研究

为探讨合成多肽体外诱导乙肝病毒抗原特异性Ｔ细胞杀伤机制，应用免疫组化检测ＨＧＶ－ＣＴＬｓＦａｓ配体表达情况，燕分析培养上清一氧化氮含量与细胞毒活性的关系。结果显示，ＨＢＶ－ＣＴＬｓ对转染ＨＢＶ ＤＮＡ的肝癌细胞存在明显的特异性细胞毒活性，其Ｆａｓ配体表达阳性率分别为５８％，５６％，明显高于ＣＤ３－ＡＫ细胞组，细胞培养上清ＮＯ含量动态分析显示，ＨＢＶ－ＣＴＬｓ细胞培养上清ＮＯ含量与细胞毒活性存在正相     

转染克隆HBVDNA的2.2.15细胞适应常规培养条件的研究

转染克隆ＨＢＶＤＮＡ的２．２．１５细胞适应常规培养条件的研究刘洪，谢建芬，张玲霞，任继明，陶陵，李泉根（中国人民解放军３０２医院病毒研究室，北京１０００３９）为了筛选抗－ＨＢＶ的有效药物，本实验室引进了具有分泌ＨＢｓＡｇ、ＨＢｅＡｇ及合成完整Ｄａｎｅ...     

针对乙型肝炎病毒前S2基因核酶的设计及体外切割 …

目的 体外研究核酶睦乙型肝炎病毒（ＨＢＶ）前Ｓ２基因的作用。方法 设计合成一针对ＨＢＶａｙｗＤＮＡ前Ｓ２区第１１０，１２２和１３２位碱基的三靶位串联锤头状核酶基因，体外转录核酶基因和靶基因并进行切割实验；将核酶基因与逆转录病毒重组，转导２．２．１５细胞观察转导细胞聚人血清白蛋白受体的表达水平。结果 核酶在体外可有产切割靶原因的转录物，转入２．２．１５细胞后４周内对ＰＨＳＡ－Ｒ表达抑制率为５１．４５     

用肾综合征出血热病毒结构蛋白体外免疫正常人外周血淋巴细胞制备单克隆抗体

用亲和层析提取的肾综合征出血热病毒（ＨＦＲＳＶ）结构蛋白（５０ｋＤ和６７ｋＤ）为抗原，在体外免疫正常人外周血淋巴细胞（ＰＢＬ）。ＰＢＬ经亮氨酸甲基酯处理后，在含有ｓＰＷＭ－Ｔ、ＩＬ－２及不同浓度抗原的培养基中培养６ｄ，计数存活ＰＢＬ数量。结果表明，在上述体外免疫条件下存活ＰＢＬ的数量与抗原剂量呈正相关。将此体外免疫的ＰＢＬ与人－鼠杂交瘤细胞（Ｋ６Ｈ６／Ｂ５）融合，获得了３株分泌抗ＨＦＲＳＶ人单抗的杂交瘤细胞，表明在体外免疫条件下，正常人ＰＢＬ能够对ＨＦＲＳＶ结构蛋白发生特异性免疫应答。     

霉酚酸对HepG2.2.15细胞中乙型肝炎病毒复制的影响

目的:探讨霉酚酸（MPA）在体外对乙型肝炎病毒(HBV)复制的影响。 方法:将不同浓度的MPA（1-20 mg/L）作用于HepG2.2.15细胞，在外加或不加鸟嘌呤核苷（简称鸟苷）的情况下，分别收集第4 d细胞培养上清，采用酶联免疫吸附试验（ELISA）检测上清中乙型肝炎病毒表面抗原（HBsAg）和e抗原（HBeAg），采用逆转录多聚酶链反应（RT-PCR）检测细胞内乙型肝炎病毒核心蛋白mRNA（HBV core mRNA）,狭缝印迹杂交法定量分析细胞内 HBV DNA。 结果:在不外加鸟苷情况下，MPA对HBV复制具有抑制作用，随着浓度增加，对HBsAg和HBeAg的抑制率逐渐上升，细胞内HBV DNA复制水平下降。外加鸟苷后能逆转MPA对HBV复制的抑制作用。 结论:MPA对HepG2.2.15细胞HBsAg和HBeAg的分泌及HBV DNA复制具有抑制作用。MPA可能通过减少细胞内鸟苷酸的合成来实现对HBV复制的抑制。     

EsiRNAs inhibit Hepatitis B virus replication in mice model more efficiently than synthesized siRNAs

RNA interference (RNAi) has been proved to be a promising strategy to combat Hepatitis B virus (HBV) infection by way of cell culture and animal model studies. In this work, esiRNAs (endoribonuclease-prepared siRNAs) targeting all of the four open reading frames (ORFs) of HBV genome were prepared. In vitro experiment showed that esiHBVP suppressed HBsAg expression most effectively. Its capacity to suppress HBV replication in vivo was then tested. A single dose of 1 microg esiHBVP was able to reduce HBsAg and HBeAg level in the mouse serum by 90 and 89% one day after injection, while the same amount of chemically synthesized siRNA only reduced that by 33 and 45%. Immunostaining of HBcAg showed that esiHBVP inhibited HBcAg expression more potently than chemically synthesized siRNA. Quantification of HBV DNA in the mouse serum showed 1 microg eiHBVP treatment reduced serum HBV DNA copy number to 18% that of the untreated control, while 1 microg siRNA treatment only reduced that to 63%. In conclusion, the data presented here proved that esiRNA is much more efficient in suppressing HBV replication than chemically synthesized siRNA, and it might be a better therapeutic agent to fight against HBV infection.     

HBV cccDNA在2.2.15细胞表达的动态观察

目的研究2.2.15细胞中是否存在HBVcccDNA,探讨2.2.15细胞内HBV产物的动态表达规律。方法采用PCR方法检测2.2.15细胞内cccDNA,Taqman定量PCR技术检测2.2.15细胞内及培养上清中HBVDNA含量,EIA方法检测培养上清中HBsAg、HBeAg的动态表达,并进行定量资料相关性统计学分析。结果2.2.15细胞及培养上清中存在cccDNA,2.2.15细胞培养上清中HBVDNA与HBsAg、HBeAg之间存在相关性(r=0.833,P<0.05和r=0.939,P<0.01),而细胞内HBVDNA与培养上清HBVDNA及HBsAg、HBeAg之间无相关性(r=0.024,P>0.05和r=0.177,P>0.05)。结论为阐明2.2.15细胞内HBV的复制规律提供一定依据。     

RNA干扰体外抑制乙型肝炎病毒抗原表达的实验研究

目的 针对乙型肝炎病毒(HBV)prec/c区构建shRNA表达载体,观察shRNA表达载体对HBV抗原表达的抑制作用,为运用RNA干扰(RNAi)技术治疗乙型肝炎奠定基础.方法 运用基因重组技术构建shRNA表达载体,经酶切,测序鉴定确认后,与1.5倍HBV真核表达质粒pHBV1.5共转染Hela细胞,并于转染后72 h,用微粒子酶免疫实验(MEIA)分别检测细胞上清液和细胞裂解液中HBsAg和HBeAg表达水平;用半定量PCR检测prec/c mRNA的转录情况;分析shRNA表达载体对HBe/HBs抗原表达的抑制情况.结果 成功构建了针对HBV prec/c区的shRNA表达载体psiHBV4、psiHBV5、psiHBV6及无关shRNA表达载体psiC;筛选到对HBeAg有明显的抑制作用的psiHBV4载体,同时其对HBsAg的表达有促进作用;psiHBV5和psiHBV6对HBeAg的抑制作用相对较弱,其对HBsAg的表达也有不同程度的促进作用;无关干扰对照psiC对HBV两种抗原的表达均无显著抑制作用.结论 成功构建带U6启动子的shRNA表达载体并初步筛选到可显著抑制HBeAg表达的psiHBV4;本研究设计的3个靶向序列中,只有一个序列有大约70%的抑制率,而另外两个序列的抑制率相对较小,说明RNA干扰作用有较强的序列依赖性;无关干扰序列psiC几乎无干扰作用,说明siRNA产生的干扰作用具有高度的特异性.以上结果为应用RNAi治疗乙型肝炎奠定了一定的基础.     

反基因锁核酸体外阻断肝癌细胞系乙肝病毒S基因表达简

 目的 探讨针对乙肝病毒S基因同聚嘌呤区的锁核酸体外抑制细胞内病毒复制的效果。方法 针对乙肝病毒S基因同聚嘌呤区设计合成锁核酸、硫代寡核苷酸、未修饰寡核苷酸及无关对照序列,以阳离子脂质体介导,体外转染HepG2.2.15细胞,采用荧光定量聚合酶链反应技术和时间分辨免疫荧光技术分别监测2、4、6、8和10 d细胞培养上清液中HBV DNA、HBsAg和HBeAg的含量;四甲基偶氮唑蓝法检测锁核酸对细胞代谢的影响。 结果 加入锁核酸后,对细胞内HBV DNA复制、HBsAg与HBeAg表达均有较明显的时间和剂量依赖性抑制作用,6 d后抑制率分别为52.14%、57.48%和29.63%。锁核酸对细胞代谢无明显影响。结论 针对乙肝病毒S基因同聚嘌呤区的锁核酸,体外能有效抑制乙肝病毒的复制,既为乙肝病毒治疗提供有效靶位,也为反基因治疗治疗提供理论和实验依据。     

RNA interference against hepatitis B virus with endoribonuclease-prepared siRNA despite of the target sequence variations

RNA interference (RNAi) has proven to be very powerful in inhibiting hepatitis B virus (HBV) replication by cell culture and mouse model studies. We have previously reported that endoribonuclease-prepared short interfering RNAs (esiRNAs) were able to inhibit HBV replication more efficiently than synthesized siRNAs. Here we tested the hypothesis that esiRNAs are able to inhibit gene expression with limited mutations within the target region. Target sequences with different similarities to esiHBVP (esiRNA targeting the DNA polymerase and S antigen of Hepatitis B virus) were amplified and cloned into the 3' untranslated region of HBsAg, respectively. When the obtained expression vectors were co-transfected with esiHBVP into CHO cells, HBsAg expression was suppressed with same efficiency regardless of the target sequence similarities. In HepG2 cells, esiHP9 based on one of the amplified sequence that sharing 87% similarity to the target region suppressed HBsAg expression effectively and dose dependently. In vivo experiment showed that a single dose of 5 microg esiHP9 was able to reduce HBsAg and HBeAg level in the mouse sera by 88 and 77% despite of its 87% similarity to the target sequence, which was as good as esiHBVP that is 100% similar to the target sequence. All the data suggest that esiRNA can tolerate limited target sequence variations without losing its inhibitory capacity. It would be very helpful to suppress virus replication by RNAi despite of their high mutation rate.     

Incidence of Hepatitis B virus DNA and DNA-polymerase in sera of Italian asymptomatic carriers with the serological markers of HBV

Summary The presence of Hepatitis B virus (HBV) DNA in sera of patients with HBV related diseases is considered a reliable marker of virus active replication. In this paper HBV DNA was assayed by the molecular hybridization method with a³²P labeled nick translated HBV probe. The assay was positive in sera of 21 out of 22 HBeAg-positive and 4 out of 8 HBeAg-negative asymptomatic HBsAg carriers. 15 HBsAg-negative sera obtained from healthy donors showed no HBV DNA. Almost 80 per cent of HBeAg and HBV DNA positive sera revealed a DNA-polymerase activity. In order to determine the infectivity of HBsAg carriers, it appears that, whenever possible, the HBV DNA spot hybridization should be performed in conjunction with the DNA-polymerase, HBsAg and HBeAg tests.With 1 Figure     

Morphologic, immunohistochemical, and ultrastructural studies of the production of hepatitis B virus in vitro

Well differentiated human hepatoblastoma Hep G2 cells after transfection with cloned hepatitis B virus (HBV) genomes produce replicative HBV DNA intermediates, high levels of HBsAg, HBeAg and HBcAg as well as mature Dane particles. To analyze the replication cycle of HBV, we studied the expression of HBV antigens with monoclonal antibodies by immunomorphologic methods in the transfected cells at various time intervals after plating. HBcAg and HBeAg were detected in the cytoplasm and less frequently in the nuclei of transfected cells. The percentage of positive cells increased with time after plating and reached a plateau of about 50% positive cells at 10 days. HBsAg and the large and middle HBsAg polypeptides were observed in the cytoplasm of transfected cells and a maximum of 20 to 30% positive cells was reached during the 3rd week after plating. Examination of viable cells in suspension revealed HBcAg/HBeAg and HBsAg expression on the cell surface. Electron microscopy demonstrated characteristic core particles in the nuclei and cytoplasm and Dane particles in cytoplasmic vesicles and culture media of transfected cells. The HBV producing cells did not show any evidence of a cytopathic effect. These observations demonstrate significant similarities between the HBV DNA transfected cells and infected human hepatocytes which support active HBV replication in vivo. Taken together, the results suggest that the cultured cells may serve as a model to elucidate a number of unsolved problems of the molecular and cellular pathobiology of hepatitis B.     

血清乙型肝炎病毒前S1抗原检测及其与病毒复制的关系

用抗Ｓ和抗前Ｓ１单抗的双抗体夹心ＥＬＩＳＡ法检测１５０例慢性乙型肝炎患者、乙型肝炎病毒表面抗原（ＨＢｓＡｇ）携带者和健康人血清中的ＨＢＶ前Ｓ１抗原，其结果和ＨＢＶＤＮＡ聚合酶链反应（ＰＣＲ）、乙型肝炎血清标志的检测结果进行比较。结果表明：前Ｓ１抗原在乙型肝炎病毒ｅ抗原（ＨＢｅＡｇ）阳性组中的检出率和相对滴度显著高于ＨＢｅＡｇ阴性组（Ｐ＜０．０１）；在ＨＢｅＡｇ阴性组中，抗－ＨＢｅ阴性人群前Ｓ１抗原的检出率和相对滴度也显著高于抗－ＨＢｅ阳性人群（Ｐ＜０．０１）。前Ｓ１抗原和ＨＢＶＤＮＡ检测结果的符合率达８０％，两者检出率的相关系数ｒ＝０．９８２６（Ｐ＜０．０１）。结论：血清前Ｓ１抗原和乙型肝炎病毒的存在关系密切。